Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease
for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants. Our localized approach represents
a significant change from the systemic immunosuppression of conventional medicines, which often have dose-limiting safety concerns and can cause serious
infections and cancer. Furthermore, through tissue-specific therapeutic targeting, Pandion’s approach has the potential to more effectively induce
and sustain response and remission in patients with many autoimmune and inflammatory conditions. We aim to shift the paradigm and create a new generation
of drugs with transformative efficacy and improved safety.
Visit Pandion's website.